VillagelinD, CooperDS, BurchHB. A 2023 international survey of clinical practice patterns in the management of Graves disease: A decade of change. J Clin Endocrinol Metab, 2024; 109(11):2956–2966; doi: 10.1210/clinem/dgae222
2.
BartalenaL, KahalyGJ, BaldeschiL, et al.;EUGOGO †. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol, 2021; 185(4):G43–G67; doi: 10.1530/EJE-21-0479
3.
BurchHB, PerrosP, BednarczukT, et al.Management of thyroid eye disease: A consensus statement by the American Thyroid Association and the European Thyroid Association. Thyroid, 2022; 32(12):1439–1470; doi: 10.1089/thy.2022.0251
4.
BartalenaL, MarcocciC, BogazziF, et al.Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med, 1998; 338(2):73–78; doi: 10.1056/NEJM199801083380201
5.
CosentinoG, LanzollaG, ComiS, et al.Ablative versus conservative approach for hyperthyroidism treatment in patients with Graves’ orbitopathy: A retrospective cohort study. Thyroid, 2025; 35(3):298–306; doi: 10.1089/thy.2024.0633
6.
BartalenaL, SmithTJ. Treatment of hyperthyroidism in Graves’ disease complicated by thyroid eye disease. J Clin Endocrinol Metab, 2025; doi: 10.1210/clinem/dgaf009
7.
MarcocciC, BartalenaL, TandaML, et al.Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: Results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab, 2001; 86(8):3562–3567; doi: 10.1210/jcem.86.8.7737
8.
MenconiF, MarinòM, PincheraA, et al.Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves’ orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab, 2007; 92(5):1653–1658; doi: 10.1210/jc.2006-1800
9.
MoletiM, VioliMA, MontaniniD, et al.Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves’ orbitopathy (GO): a prospective, randomized, single-blind clinical trial. J Clin Endocrinol Metab, 2014; 99(5):1783–17899; doi: 10.1210/jc.2013-3093
10.
TallstedtL, LundellG, BlomgrenH, et al.Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur J Endocrinol, 1994; 130(5):494–497; doi: 10.1530/eje.0.1300494
